Bartels G L, Remme W J, Wiesfeld A C, Kok F J, Look M P, Krauss X H, Kruyssen H A
Cardiovascular Research Foundation, Sticares, Rotterdam, The Netherlands.
Cardiovasc Drugs Ther. 1990 Jun;4(3):705-12. doi: 10.1007/BF01856558.
The duration and reproducibility of hemodynamic effects of flosequian, a direct-acting, balanced-type vasodilator, were studied in 19 heart failure patients (NYHA class 3.0 +/- 0.7) receiving 100 mg orally (day 1), placebo (day 2), and again 100 mg (day 3). Flosequinan immediately reduced systemic and pulmonary resistance (23% and 35%, respectively, at 60-90 minutes postdrug) and decreased pulmonary wedge, right atrial, mean pulmonary artery, and mean arterial pressure by 38%, 50%, 25%, and 7%, respectively. Concomitantly, cardiac output, and stroke volume and work increased by 26%, 20%, and 22%, respectively. Most hemodynamic effects persisted for 48 hours. In contrast, changes in pulmonary wedge and arterial pressures, stroke volume, and stroke work only lasted for 2-12 hours. Maximum absolute changes on day 3 were generally comparable with first-dose effects with, again, long-lasting effects on systemic resistance and cardiac output. However, changes in pulmonary artery, wedge, and resistance were significantly shorter than after first dose administration. These data indicate sustained and reproducible arterial dilating effects of flosequinan, but less pronounced and shorter lasting pulmonary arterial and venodilator properties.
在19例心力衰竭患者（纽约心脏协会心功能分级为3.0±0.7级）中，研究了直接作用的平衡型血管扩张剂氟司喹南血流动力学效应的持续时间和可重复性。患者口服100mg氟司喹南（第1天）、安慰剂（第2天），然后再次口服100mg（第3天）。氟司喹南可立即降低体循环和肺循环阻力（给药后60 - 90分钟时分别降低23%和35%），并使肺楔压、右心房压、平均肺动脉压和平均动脉压分别降低38%、50%、25%和7%。同时，心输出量、每搏输出量和作功分别增加26%、20%和22%。大多数血流动力学效应持续48小时。相比之下，肺楔压和动脉压、每搏输出量及每搏作功的变化仅持续2 - 12小时。第3天的最大绝对变化通常与首次给药效应相当，对体循环阻力和心输出量仍有持久影响。然而，肺动脉、肺楔压及阻力的变化明显短于首次给药后。这些数据表明氟司喹南具有持续且可重复的动脉扩张作用，但肺动脉和静脉扩张特性不那么明显且持续时间较短。
